NuVision Biotherapies, a tissue-based technology company delivering ophthalmic and wound care solutions in the primary care and surgical setting, join the conference to increase their international profile and to develop new distributor relationships.
As a spin-out from the University of Nottingham, NuVision Biotherapies (www.nu-vision.co.uk) platform technology the Tereo® process delicately preserves amniotic membrane tissues in a dry, stable, and easy to handle format. Amniotic membrane is the innermost layer of the placental sac, that supports and nurtures a baby while in the womb. These tissues are collected from consenting mothers and are upcycled into a transplantable material that can support wound healing; reduce inflammation development and aid pain management in a range of ophthalmic and chronic wound disease areas.
Secondary to Tereo processed amniotic membrane, NuVision have also developed OmniLenz®, a bandage contact lens specially designed and developed with Menicon Ltd (https://www.menicon.co.uk) to effectively apply and retain Omnigen, Tereo processed amniotic membrane to the ocular surface. OmniLenz application of Omnigen is a simple 4–6-minute procedure eliminating the need for sutures or surgery. This uniquely allows transplantation of amniotic membrane e in an outpatient setting. In clinic application of Omnigen is transforming the management of an ocular surface disease.
NuVision Biotherapies are joining Arab Health following support from the UK’s Department of International Trade – Midlands’ branch following grant-funded support from the organisation and will exhibit alongside a range of healthcare companies (https://eu.eventscloud.com/ehome/index.php?eventid=200237455&). The drive of NuVision’s international growth and relationships come as they look to develop their global partnerships and increase access to their product portfolio.
Dr. Andrew Hopkinson, Founder and Chief Scientific Officer stated: “We are excited to be able to directly reengage with the international arena, and Arab Health is the perfect platform to achieve this. The innovation our Tereo processed amniotic membrane products offer to the ophthalmology and wound care markets were intentionally developed to benefit patients and health care professionals worldwide. We are therefore looking forward to the networking opportunities and forging new strategic commercial partnerships to distribute our products.”
Arab Health is taking place from the 24th – 27th of January 2022 at the Dubai World Trade Centre. NuVision will be exhibiting at stand number: R.R72. Please pop down to see us to gather further information or contact firstname.lastname@example.org to book an appointment with one our team in.
Based in MediCity, Nottingham, NuVision Biotherapies is a regenerative medicine company spun out from the University of Nottingham. NuVision was established in 2015.
Omnigen Tereo processed amniotic membrane, is a patented dry preparation of human amniotic membrane. Amniotic membrane is the innermost layer of the placental sac, which protects and holds the foetus during pregnancy. NuVision upcycles and transforms this waste product of birth into an effective wound care product. The Tereo manufacturing process, developed at the University of Nottingham’s Academic Ophthalmology department, transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The Tereo process preserves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from ocular surface disease and conditions with unmet medical need.
OmniLenz is a bespoke BCL designed to apply and hold Omnigen at the ocular surface without the need for sutures or surgery. OmniLenz is manufactured exclusively for NuVision by Menicon, UK. Omnigen can be applied by OmniLenz using a simple 4 – 6-minute procedure in an outpatient setting. The decision to apply Omnigen to the ocular surface using OmniLenz is at the discretion of the clinician.